VRTX · 10-Q · 2026Q2 · Full report
Regulatory Approval Milestones
VERTEX PHARMACEUTICALS INC / MA · 2026-08-04 · Importance 47 · Surprise 60 · In source text
The FDA approved CASGEVY for children at least two years old with sickle cell disease or transfusion-dependent beta thalassemia, potentially adding approximately 5,500 eligible patients. Vertex completed submissions in Saudi Arabia and the United Kingdom for CASGEVY in children ages five to eleven and secured German reimbursement for patients age 12 and older. The FDA accepted povetacicept’s IgA nephropathy application for accelerated approval and set a November 30, 2026 PDUFA target action date. Health Canada also accepted suzetrigine’s application for acute pain, while Saudi Arabia granted povetacicept Breakthrough Designation.
Key facts
- FDA accepted biologics license application for accelerated approval of povetacicept for adults with IgAN and assigned a PDUFA target action date of November 30, 2026 source
- FDA approved CASGEVY in children two years of age and older with SCD or TDT, making it the first genetic therapy indicated for children as young as two source
- Completed regulatory submission for accelerated approval of povetacicept in adults with IgAN in Saudi Arabia; Saudi FDA granted Breakthrough Designation to povetacicept source
- Expect to share interim analysis data from the AMPLITUDE trial in early 2027 and to conduct the pre-planned interim analysis for potential U.S. accelerated approval once the interim analysis cohort has been treated for 48 weeks source
- Regulatory submissions completed in Saudi Arabia and the United Kingdom for treatment of children five to eleven years of age with CASGEVY source
- Initiated global regulatory submissions for ALYFTREK in children with CF two to five years of age following positive Phase 3 results source
- Health Canada accepted new drug submission for suzetrigine for moderate-to-severe acute pain during Q2 2026 and review is underway source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | positive | probable | — | FDA accepted biologics license application for accelerated approval of povetacicept for adults with IgAN and assigned a PDUFA target… |
| revenue | positive | probable | — | FDA approved CASGEVY in children two years of age and older with SCD or TDT, making it the first genetic therapy indicated for children as… |
| revenue | positive | probable | — | Completed regulatory submission for accelerated approval of povetacicept in adults with IgAN in Saudi Arabia; Saudi FDA granted… |
| revenue | positive | contingent | — | Expect to share interim analysis data from the AMPLITUDE trial in early 2027 and to conduct the pre-planned interim analysis for potential… |
| revenue | positive | probable | — | Regulatory submissions completed in Saudi Arabia and the United Kingdom for treatment of children five to eleven years of age with CASGEVY |
| revenue | positive | probable | — | Initiated global regulatory submissions for ALYFTREK in children with CF two to five years of age following positive Phase 3 results |
| revenue | positive | probable | — | Health Canada accepted new drug submission for suzetrigine for moderate-to-severe acute pain during Q2 2026 and review is underway |